Background. Renoprotective actions of angiotensin receptor blockers are not well established in normotensive, lowgrade proteinuric glomerular diseases. We examined the effect of low-dose telmisartan (LT) and high-dose telmisartan (HT) versus conventional antihypertensive therapy in the rat anti-Thy1.1 model of glomerulonephritis.
Introduction
Mesangioproliferative immunoglobulin A nephropathy (IgAN) is the most common pattern of idiopathic glomerulonephritis (GN) worldwide [1] . Twenty-five to 30% of all patients develop end-stage renal disease. Additionally, recurrence of IgAN after renal transplantation becomes increasingly important [2] . The effects of renin-angiotensin system (RAS) blockade have been investigated both in human IgAN and animal models of mesangioproliferative GN.
In humans, optimal blood pressure control achieved by angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin II receptor blockers (ARB) is beneficial in proteinuric IgAN patients [3] . Nevertheless, the efficacy of RAS blockade beyond lowering of blood pressure is still questioned. Interestingly, experimental evidence suggests that a very high dose of ACE inhibition [4] or ARB [5] may provide additional benefit, consistent with the higher activity of the RAS in the kidney compared to plasma.
In the normotensive rat anti-Thy 1.1 model of mesangioproliferative GN [6] , mesangiolysis is induced by a complement-fixing antibody against the Thy 1.1 antigen on the mesangial cell surface. This is followed by mesangioproliferative glomerular changes, recruitment of inflammatory cells and extracellular matrix deposition. The course of the disease is self-limiting and nephritic changes mostly disappear in 4-6 weeks after the induction of disease.
ACE inhibitors and ARBs ameliorate the course of the GN [7] [8] . These experimental studies failed to address such relevant clinical issues as dose-related efficacy, timing of initiation of treatment after GN is established and nonhaemodynamic effects of RAS blockade. Furthermore the mechanisms underlying the nephroprotective effect of ARBs still remain speculative.
The aims of the study were to answer the following questions: (i) Is ARB treatment effective if started when the nephritis is already fully established? (ii) Does ARB treatment exert pleiotropic effects in addition to and at least in part independent of blood pressure lowering? (iii) Does the renal benefit of an ARB exceed that of a antihypertensive treatment with hydrochlorothiazide and hydralazine (HCT 1 H), which controls systemic hypertension but fails to limit glomerular damage given its absent effect on intraglomerular hypertension [9] ? (iv) Which potential mechanisms contribute to ARB-induced amelioration of nephritis? To address the above questions, treatment was initiated on Day 4 after the induction, at the time when the rat anti-Thy 1.1 GN is already full blown. Renal changes were then assessed on Day 9, i.e. during the peak of the mesangioproliferative phase, and on Day 14, i.e. the time point of maximum matrix accumulation.
Materials and methods

Experimental design
All animal experiments were approved by the local review boards. Animals were held in rooms with constant temperature, humidity and 12 h/12 h light cycles. Daily fluid intake was measured, and the different treatment groups were pair fed (normal chow diet).
Forty-eight male Lewis Hannover rats (weighing 150-200 g; Harlan, Horst, The Netherlands) received an intravenous injection of anti-Thy 1.1 antibody (clone OX7; European Collection of Animal Cell Cultures, Salisbury, England) and 1 mg/kg of body weight (BW). Four days after disease induction, 24-h urine collection was performed and rats were allocated according to an equal degree of proteinuria and blood pressure into four experimental groups: CT: control group (n ¼ 12)-tap water; LT: low telmisartan group (n ¼ 12)-0.1 mg/kg BW/day of telmisartan (Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany); HT: high telmisartan group (n ¼ 12)-10 mg/kg BW/day of telmisartan (Boehringer Ingelheim Pharma GmbH & Co.KG) and HCT 1 H: 'conventional' antihypertensive therapy group (n ¼ 12)-8 mg/kg BW/day of hydrochlorothiazide and 32 mg/kg BW/day of hydralazine (both from Sigma-Aldrich, Munich, Germany).
Doses were chosen according to unpublished pilot studies that we performed in the same rat strain after induction of anti-Thy1.1 nephritis. A 100-fold difference between the doses of telmisartan was chosen given experimental data of Boehringer Ingelheim that showed that only such a difference ensures discrimination of haemodynamic and nonhaemodynamic effects.
Telmisartan was first dissolved into an alkaline solution (1 N NaOH), which was subsequently neutralized to pH 7.4 by adding an acid solution (32% HCl). All substances were then dissolved in the drinking water and prepared fresh every 2 days. The dosage was adjusted according to the BW and water intake. Blood pressure was measured on Days 0 and 4 and 1 day before sacrifice, followed by a 24-hour urine collection. Six rats from each group were sacrificed on Days 9 and 14, respectively, after disease induction. Venous blood was collected and glomeruli and renal cortical tissue were obtained for immunohistochemistry, gene expression analysis and expression arrays.
Renal morphology and immunohistochemistry
Tissue for light microscopy and immunoperoxidase staining was fixed in methyl Carnoy's solution as well as in formalin and embedded in paraffin. Four micrometer sections were stained with Sirius red or with the periodic acid-Schiff reagent and counterstained with haematoxylin [10] . Glomerular mitoses, mesangiolysis and Sirius red staining were assessed as described [11] [12] [13] .
Indirect immunoperoxidase staining was done as described previously [10, 12] . Glomerular infiltrating ED1-positive monocytes/macrophages were counted in 100 glomeruli per tissue and mean values per glomerulus were calculated. The expression of a-smooth muscle actin and collagen type IV was evaluated by computer-based morphometry as described previously [13] .
Double immunostaining for the identification of damaged podocytes was performed by first staining with a rabbit polyclonal antibody to the human nuclear antigen Wilms' Tumor 1 (WT-1; Santa Cruz, Heidelberg, Germany) followed by staining with a mouse monoclonal antibody to human desmin (clone D33; DAKO) as described [11] . Cells were identified as damaged podocytes if they showed positive nuclear staining for WT-1 and if the nucleus was surrounded by cytoplasm completely positive for desmin. The number of double-positive cells was assessed in 100 consecutive glomerular cross sections per animal.
Staining of Discs large homolog-1 (Dlgh-1) was performed using the same antibody for immunocytochemistry as described in the cell culture and immunocytochemistry section.
Evaluation of all slides was performed by an observer who was unaware of the origin of the slides
Cell culture and immunocytochemistry
Primary rat mesangial cells were cultured in DMEM medium with 10% fetal calf serum (FCS), 1% penicillin-streptomycin, 1% L-glutamine, 0.5% insulin-transferrin-selenium supplement, 1% amphotericin B (all from Invitrogen GmbH, Darmstadt, Germany), rat-immortalized renal fibroblasts (NRK-49F) in DMEM medium with 5% FCS, rat-immortalized renal tubular cells (NRK-52E) in DMEM medium with 10% FCS, 1% penicillinstreptomycin and 1% L-glutamine. Immortalized mouse podocytes (WT-5) were cultured and differentiated according to Mundel et al. [14] .
For immunocytochemistry, cells were cultured until 50-75% confluence on cover slips into 12-well plates (Corning Life Sciences, Amsterdam, The Netherlands).
Cover slips were washed and the cells fixed and permeabilized with ice-cold acetone (Sigma-Aldrich Biochemie Gmbh, Hamburg, Germany) for 5 min at À20°C. After washing, cover slips were incubated for 30 min at room temperature with a blocking solution prepared with 1% bovine serum albumin (BSA; Sigma Aldrich Biochemie GmbH) in phosphatebuffered saline (PBS) (Invitrogen). After washing, cells were incubated for 1 h at 37°C with primary antibodies directed against rat angiopoietinlike 4 (Angptl-4) and Discs large homolog-1(Dlgh1) (rabbit polyclonal against Angptl-4, 1:500 dilution, ab2920; Abcam, Cambridge, UK and rabbit polyclonal against discs large homolog 1, 1:500 dilution, ab3437; Abcam). After washing, the cells were incubated with a fluorescent secondary antibody (Cy3-conjugated goat anti-rabbit, 1:100 dilution; Jackson Immunoresearch Laboratories Inc., West Grove, PE) for 30 min at room temperature in the dark. After washing, the cells were counterstained with 1 lg/ml 4#,6-diamidino-2-phenylindole working solution (Roche Applied Science, Mannheim, Germany) for 10 min at room temperature in the dark and then mounted onto object tray slides using Vectashield mounting medium (Vector Laboratories Inc., Burlingame, CA). Images were taken using a fluorescence optical microscope (Leica Mikrosysteme Vertrieb GmbH, Wetzlar, Germany). All washing steps were performed with PBS (Invitrogen Gmbh) and antibodies were diluted in a 1% BSA/PBS solution. Control-negative staining was performed by using appropriate isotypic immunoglobulins instead of the specific antibodies.
Gene expression analysis arrays
Renal tissue obtained on Day 14 from three rats of each treatment group was used. Renal cortical amplified RNA (aRNA) from each rat was individually hybridized to a chip (Affymetrix GeneChipÒ Rat Genome 230 2.0 Array).
Kidney cortex samples were stored overnight at 4°C in RNAlater solution (Ambion Inc., Austin, TX) and then at À80°C. To extract RNA, the tissue was homogenized and RNA isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA sample collection and generation of biotinylated complementary RNA probes were carried out according to the instructions of Affymetrix (Santa Clara, CA, USA). Total RNA (3.1 lg of each sample) was reverse transcribed into double-stranded complementary DNA (cDNA) using high-performance liquid chromatographypurified T7-(dt) 24 primers and the GeneChipÒ Expression 3# Amplification one-Cycle Target Labelling and Control Reagents-Kit (Affymetrix). The purified double-stranded cDNA was used to synthesize biotinylated complementary aRNA probes.
Each aRNA sample was hybridized to a chip for 16 h at 45°C and 60 r.p.m. The arrays were washed and stained according to the program EukGE-WS2v5 using the Fluidics Station 450 and eventually they were scanned using the GeneChip Ò Scanner 3000, updated for high resolution (Affymetrix).
Only genes that were detectable in all three chips per group and whose expression levels were changed significantly (P < 0.05) were included in the analyses. Expression analysis was performed using Bioconductor [15] packages under R 2 [16] . Background correction and normalization was done with the algorithm GCRobust Multi-array Average (GCRMA) [17] . MAS 5.0 (Affymetrix) was used to make detection calls for every probe set [18] . Linear models were fitted for each gene from all four target groups, followed by an empirical Bayes estimation [19] . BenjaminiHochberg's method, which controls the false discovery rate, was used to adjust for multiple testing [20] .
Signalling pathways were analysed with the Ingenuity Pathways Analysis software according to the manufacturer's instructions (Ingenuity Ò Systems Inc., Redwood City, CA).
Significant regulation of genes discovered by gene expression analysis arrays was confirmed by quantitative real-time polymerase chain reaction (PCR) as described in the 'RNA extraction and analysis' section below.
RNA extraction and analysis
Total RNA extraction from whole cortex and glomeruli, cDNA synthesis and real-time-quantitative reverse transcriptase PCRs were performed as described [12] . Isolation of glomeruli was performed by differential sieving as previously described [12] . Sequences of primers used for PCR are listed in Table 1 . Specific messenger RNA (mRNA) level of each sample was normalized to the expression of the house-keeping gene hypoxanthine-guanine-phosphoribosyltransferase.
Miscellaneous analyses
Systolic blood pressure (SBP) was measured by tail-cuff plethysmography (BP-981; Softron, Tokyo, Japan) in conscious trained rats. The means of three measurements for each animal were calculated per time point. In our hands, by using standardized procedures in trained animals, the tail-cuff measurement method has a very high reproducibility. Also, this method exhibits a highly significant correlation with telemetric methods [21] .
Urinary protein, creatinine levels and serum potassium were measured by an autoanalyser.
Statistical analysis
Statistical analyses used for gene expression analysis arrays are described in the specific sections.
All remaining data were analysed using the software SPSS 12.0 for Windows (SPSS Inc., Chicago, IL). Results are presented as means AE SDs. Groups were compared using analysis of variance followed by Bonferroni's post-hoc tests. A probability (P) value <0.05 was considered statistically significant.
Results
Functional parameters
At baseline (Day 0), proteinuria was <20 mg/day in all rats and all animals were normotensive without differences in SBP (mean 111 AE 14 mmHg).
At the time of allocation to the different groups (Day 4), all animals exhibited similar proteinuria (mean 245 AE 84 mg/day), SBP levels (mean 107 AE 15 mmHg) and BW (178 AE 18 g); no difference in any parameter existed among the different groups (Table 2) .
At Day 9, but not at Day 14, treatment with HT and HCT 1 H significantly reduced blood pressure compared to controls ( Table 2 ). All animals remained normotensive at both time points.
At Day 9, serum creatinine and creatinine clearance were significantly higher and lower, respectively, in the HCT 1 H group; on Day 14, serum creatinine only remained significantly higher in the HCT 1 H group.
At Day 9, both HT and HCT 1 H significantly reduced urinary protein excretion in comparison to the other groups (Table 2) .
BW was significantly lower in HCT 1 H-treated animals versus CT and LT at Day 9; however, at Day 14, this difference did not persist, but rats receiving HT had significantly higher BW compared to CT and HCT 1 H ( Table 2) .
Normalization of creatinine clearance and 24-h proteinuria for BW did not affect the results (data not shown).
Glomerular damage
At Day 9, residual mesangiolysis (data not shown) and glomerular cell proliferation ( Figure 1) were not different between the groups. At Day 14, all treatments reduced endothelial cell proliferation by 47-71% compared to CT animals ( Figure 1 ).
Mesangial cell activation, as assessed by glomerular de novo alpha-smooth muscle actin expression, was reduced by 40% by HT at Day 14 as compared to CT (Figures 1 and 2) .
At Day 9, HT treatment also reduced podocyte damage, as shown by counting cells positive for both WT-1 and desmin (À72% versus CT, P < 0.05) (Figure 1) .
No treatment significantly affected counts of glomerular monocytes/macrophages at Days 9 and 14 ( Figure 1 ). Glomerular matrix deposition was assessed by Sirius red staining. At Day 14, HT and LT treatments significantly diminished the Sirius red-positive area as compared to CT (Figure 1) . HCT 1 H treatment reduced glomerulosclerosis to a lesser extent.
Tubulointerstitial damage
Glomerular changes in the anti-Thy 1.1 GN model are accompanied by secondary tubulointerstitial damage. HT significantly reduced alpha-smooth muscle actin expression around damaged tubules at Day 14 (À44% versus CT, LT P < 0.05), whereas at Day 9, it increased with HCT 1 H treatment (136% versus CT, P < 0.05) ( Figures  1 and 2) .
At Day 14, LT and HT reduced the Sirius red-positive area to a greater extent compared to HCT 1 H (Figure 1) . Furthermore, HT only reduced collagen type IV in comparison to CT (Figures 1 and 2 ).
In addition to matrix deposition, we assessed tubular cell dedifferentiation, during which renal tubular cells lose surface markers such as E-cadherin and start to express markers, such as vimentin [22, 23] . HT treatment reduced the loss of E-cadherin at Day 9 (161% versus CT, P < 0.05) and vimentin overexpression at Day 9 (À35% versus CT, À25% versus LT, À30% versus HCT 1 H, P < 0.05) ( Figure 2 ) and Day 14 (À22% versus HCT 1 H, P < 0.05) (Figure 1 ).
Gene expression profiles
Since the acute phase of anti-Thy 1.1 nephritis is characterized by both glomerular and tubulointerstitial damage, we used renal cortical mRNA for the gene expression analysis arrays.
Gene expression analysis was performed using two approaches: on the one hand by comparing the expression level of single genes and on the other hand by comparing groups of genes clustered in biological pathways.
To answer our experimental questions, we performed for both approaches a preliminary screening of the gene expression with the following comparisons: (i) rats treated either with LT, HT or HCT 1 H versus untreated rats (CT) to explore the mechanism of action for every regimen, (ii) rats treated with HT versus LT to investigate dosedependent ARB effects and (iii) rats treated with HT versus rats treated with HCT 1 H to assess effects of ARB that may extend beyond blood pressure lowering.
Semiquantitative classification of the single gene changes observed (Table 3 ) revealed gradual differences between LT and CT, whereas the difference between HT and HCT 1 H was more pronounced. Furthermore, Table 1 . Sequences of primers used for real-time reverse transcriptase PCR [5#-3# direction for rat hypoxantine-guanine phosphoribosyltransferase (rHPRT); rat Angptl-4 (rANGPTL); rat discs large homolog 1 (rDLGH1)]
Gene
Forward primer Reverse primer (Tables 4  and 5) shows that in general treatment-induced gene suppression was more widespread and more pronounced than upregulation. We then decided to focus our investigation on downregulated genes only. Furthermore, as the major beneficial effect of ARBs was demonstrated with the high dose (HT) in functional and histological analyses, we concentrated on the most regulated genes in the comparisons between the HT and the CT (effect of high dose) as well as HT and LT (dose-related effect) groups. Out of the various regulated genes, we focused on Dlgh1, a scaffold protein, and Angptl-4, a member of the angiopoietin family of secreted proteins, given their prominent quantitative downregulation and potential biological relevance (see Discussion section). Furthermore, Dlgh1 was chosen as the pivotal gene for the dose-related effect, as it is not only downregulated by HT in comparison to CT but also in comparison to LT. A full overview of significantly regulated genes is given in Supplementary Table 1 .
To verify the array findings, the expression of Angptl-4 and Dlgh1 was confirmed by quantitative real-time PCR (Supplementary Table 2 ) in cortical and glomerular samples and analysed by immunocytochemistry (see section below).
We then investigated clustering of genes in specific signaling pathways. Data regarding significantly regulated pathways (and correspondent genes) are shown in Table 6 . The most prominent regulation of pathways related to (i) the effect of high-dose ARBs [HT versus CT; for example insulin receptor signalling and mammalian target of rapamycin (mTOR)], (ii) the dose-related effect of telmisartan (HT versus LT; for example insulin receptor signalling, mTOR, vascular endothelial growth factor (VEGF), phosphatase and tensin homolog (PTEN) and neuregulin] and (iii) effects which appeared largely independent of blood pressure lowering (HCT 1 H versus HT; for example hypoxia signalling and protein ubiquitination) ( Table 6 ).
Expression of Angptl-4 and Dlgh1
Glomerular expression of Angptl-4 and Dlgh1 was significantly reduced by HT treatment and the lowest Angptl-4 and Dlgh1 expression was observed in glomeruli of rats treated with HT ( Figure 3A) .
The protein expression of Angptl-4 and Dlgh1 was also investigated in various renal cell types by immunocytochemistry. Rat mesangial cells expressed Dlgh1 but not Angptl-4, whereas podocytes showed a strong expression of both proteins. Kidney fibroblasts expressed neither Dlgh1 nor Angptl-4, whereas Dlgh1 only was expressed in kidney epithelial cells ( Figure 3B) .
Consistent with the in vitro data, in vivo Dlgh-1 was expressed in the cytoplasm and the nucleus of podocytes, in the nuclei of mesangial cells and in the nuclei and the basal portion of the cytoplasm of tubular cells, the latter being positive in some tubular segments only ( Figure 3C ).
Discussion
In previous studies [7] [8] describing the beneficial effects of ACE inhibitors/ARBs in the anti-Thy 1.1 GN model, treatment was initiated prior to or at the time of disease Effects and mechanisms of angiotensin II receptor blockadeinduction. Previously Liu et al. [24] investigated the effect of high-dose olmesartan in the same animal model but their results are difficult to compare with our ones for several reasons. The most striking discrepancy is that high-dose olmesartan failed to reduce blood pressure in comparison to untreated rats. Our study is the first to examine a clinically more relevant situation, i.e. starting treatment at the stage of full-blown GN. Our experimental design also allowed us to better account for interindividual variations in disease manifestation since we allocated animals to the various groups based on their degree of proteinuria. This improves the ability to detect small effects of low-dose ARB treatment since in prior studies, the effects of ARBs or ACE inhibitors were often minor when major blood pressure lowering was not achieved [8] . Ours is also the first study to include a 'conventional' antihypertensive treatment group in order to dissect the haemodynamic and potential nonhaemodynamic mechanisms of ARB treatment. In addition, as glomerular hypertension plays a major role in the development of renal damage, we included a group treated with HCT 1 H, which does not affect intraglomerular pressure [9] . Finally, the anti-Thy 1.1 GN offers the unique possibility to study a model of progressive renal failure induced by anti-Thy 1.1 antibody plus a uninephrectomy or a spontaneously reversible renal disease. In the present experiment, we preferred the latter since the model is not confounded by glomerular hyperfiltration and by early adaptive renal hypertrophy.
The first major finding of our study was that only a high dose of ARBs reduced both glomerular and the secondary tubulointerstitial damage. At the peak of nephritic activity (Day 9), only the high dose but not the low dose of telmisartan exerted a potent antiproteinuric action. HCT 1 H also lowered proteinuria by 35%, but most likely due to a 38% reduction of glomerular filtration rate, which was possibly caused by diuretic-induced dehydration. As part of the spontaneous disease resolution, proteinuria decreased between Days 9 and 14 and treatment-related differences in proteinuria did not persist.
Glomerular endothelial cell proliferation and mesangial cell activation were most intensely reduced by HT. Both of these processes characterize the nephritic phase of anti-Thy 1.1 GN [25, 26] . In our study, HT but not LT treatment significantly reduced podocyte damage on Day 9, which is consistent with the reduction of proteinuria. In contrast to prior observations regarding RAS inhibition [8] , ARB administration did not affect glomerular monocyte/macrophage infiltration. This may be related to the fact that we initiated treatment at a later nephritis stage, when leukocyte recruitment is mostly completed. Finally, glomerular matrix expansion, as assessed by Sirius red, was markedly reduced by both LT and HT. Fig. 2 . Representative images of alpha-smooth muscle actin, type IV collagen and vimentin expression in the CT, LT, HT and HCT 1 H group, respectively (magnification 3100 for alpha-smooth muscle actin and collagen IV, 3200 for vimentin). We [27] and others [28] [29] [30] [31] have previously described that secondary renal interstitial damage accompanies glomerular injury in early anti-Thy 1.1 GN. In line with this, HT reduced interstitial matrix expansion, mainly by inhibiting tubular cell dedifferentiation and activation of myofibroblasts.
The second major finding of this paper was the elucidation of mechanisms accounting for the efficacy of highdose ARB and the discovery of new potential candidate molecules and signalling pathways underlying the pleiotropic effects of ARBs. To study the mechanisms of renoprotection, we next performed a genomic analysis of the kidneys. Gene expression analysis array experiments showed a profound alteration in gene expression in the HT and HCT 1 H groups if compared to CT, while LT evoked a milder perturbation. A novel observation is that HCT 1 H treatment, previously considered 'neutral' in terms of therapeutic efficacy, induced such prominent transcriptional alterations.
We identified Dlgh1 and Angptl-4 as candidate genes underlying the beneficial effect of HT.
Dlgh1 is a scaffold protein, which is fundamental for podocyte polarization [32] . Cell polarity regulates the podocyte cytoskeleton and cell shape and eventually the response to cell damage [32] . In our study, we showed not only the protein expression of Dlgh1 in podocytes but also its downregulation under high-dose ARBs, which strongly correlates with the reduction of proteinuria and podocyte damage. Angptl4 is a glycoprotein that is structurally related to angiopoietin and it modulates lipid metabolism. In puromycin aminonucleoside nephrosis, a peroxisome proliferatoractivated receptor (PPAR)-gamma agonist improved the course of disease and reduced the expression of Angptl-4 [33] , which is consistent with telmisartan acting as a partial PPAR-gamma agonist [34] . Of notice, no information regarding the specific differential renal expression of Angptl-4 has been previously described [33] . Recent published results of Clement et al. [35] showed a pivotal role of Angptl-4 in the pathogenesis of glomerular diseases, in particular minimal-change nephropathy. In our study, we could demonstrate the expression at the protein level in podocytes only and we showed that telmisartan downregulated the expression of Angptl-4, which correlates with the amelioration of proteinuria and podocyte damage due to high-dose ARBs largely independently of blood pressure lowering.
Furthermore, we discovered further pleiotropic effects of ARBs by the assessment of signalling pathways.
High-dose modulation of insulin signalling by ARBs through downregulation of serum/glucocorticoid-regulated kinase 1 (SGK-1) could represent an additional beneficial anti-fibrotic mechanism. In fact, SGK-1 contributes to hypertension by stimulating sodium intake and retention and is overexpressed in fibrosing kidneys [36] .
Another candidate, mTOR pathway, may be involved in renal scarring, as indicated by the benefit of the treatment with rapamycin in rodent models of progressive kidney disease [37] .
The dose-related effect of ARBs correlated also with the downregulation of other growth factor signalling, namely VEGF, PTEN and neuregulin. The function of VEGF in anti-Thy 1.1 nephritis is not well defined since it can both contribute to capillary regeneration [11] and, in other 
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Effects and mechanisms of angiotensin II receptor blockademodels, to glomerular hypertrophy and microalbuminuria [38, 39] . No data regarding the role of PTEN and neuregulin in renal disease are so far available. We could find a significant regulation of the Wnt/betacatenin/transcription factors (TCF) signalling pathway that was related to the mild effect of LT on fibrosis. Sex determining region Y (SOX) transcription factors are negative regulators of the profibrotic Wnt-beta-catenin-TCF signalling pathway [40, 41] . In murine unilateral ureteral obligation, inhibition of Wnt/beta-catenin indeed reduced renal fibrosis [42] . Reduced activity of the Wnt/betacatenin pathway in telmisartan-treated rats may also explain the reduction of tubular cell dedifferentiation in these groups [43] . Regarding the mechanisms underlying the effects of high-dose ARBs in addition to blood pressure lowering, we discovered two significant biological pathways. With respect to hypoxia signalling, HT reduced the expression of genes related to hypoxia-inducible factor 1 (HIF1)-alpha ubiquitination that plays a fundamental role in HIF1-alpha protein degradation. Activation of HIF has been shown to ameliorate injury in Thy-1.1 nephritis, most likely through the induction of cytoprotective factors and by promoting angiogenesis [44] . In the current paper, we used a model of acute kidney injury; therefore, the inhibition of HIF-1alpha degradation could underlie amelioration of nephritis.
Finally, dowregulation of protein ubiquitination by highdose ARB treatment suggests reduced proteasomal degradation of proteins as a further additive mechanism to the mere antihypertensive effect of ARBs. Various ubiquitin ligases are involved in the dedifferentiation of tubular cells and transforming growth factor-beta signalling [45] [46] [47] and blockade of the proteasome reduced cardiac fibrosis in spontaneously hypertensive rats [48] .
In summary, we found that a high dose of telmisartan offers new potent renoprotective effects that could not be obtained with either low-dose telmisartan or a diureticvasodilator combination. Furthermore, we provide the first comprehensive transcriptomic profiling of the effects of ARBs and conventional antihypertensive treatment in experimental GN. We identified two novel candidate genes, namely Dlgh1 and Angptl-4, which may be involved in the modulation of glomerular and tubulointerstitial damage. We further identified a number of signalling pathways potentially related to the pleiotropic effects of ARBs, which will serve as a reference basis for future studies, focusing on potentially new pathomechanisms by which high-dose ARBs affect renal disease.
Supplementary data
Supplementary Tables 1, 2 and a colour version of Figure  3B are available online at http://ndt.oxfordjournals.org.
